Canakinumab Brand Name– Ilaris
What is Canakinumab
Canakinumab is a human monoclonal antibody against interleukin (IL)-1 beta approved for the treatment of 2 forms of cryopyrin-associated periodic syndromes (CAPS), Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in patients 4 years of age and older.
Canakinumab is also approved for adult and pediatric patients for Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), and Familial Mediterranean Fever (FMF). In addition, canakinumab is approved for active Still’s disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older.
Most patients with FCAS and MWS respond positively to canakinumab. For example, 34 of 35 patients who received a single 150 mg canakinumab subcutaneous dose had a complete response, which was defined as a physician global assessment of no or minimal disease activity, an assessment of no or minimal rash, and a C-reactive protein and serum amyloid A protein concentration less than 10 mg/L.
The patient without a complete response had self-injected the drug and had substantially lower than expected canakinumab concentrations.
Continued remission was achieved by all patients who received canakinumab every 8 weeks through week 24.
Indications
- coronavirus disease 2019 (COVID-19)
- cryopyrin-associated periodic syndromes (CAPS)
- familial mediterranean fever
- hyperimmunoglobulin D syndrome
- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
- Still’s disease
- systemic juvenile idiopathic arthritis
- tumor necrosis factor receptor associated periodic syndrome
For the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS)
Side Effects
- abdominal pain
- antibody formation
- cough
- diarrhea
- elevated hepatic enzymes
- headache
- hyperbilirubinemia
- hypotension
- immunosuppression
- infection
- influenza
- injection site reaction
- leukopenia
- macrophage activation syndrome
- musculoskeletal pain
- nausea
- neutropenia
- new primary malignancy
- palpitations
- pharyngitis
- pruritus
- rash
- rhinitis
- sinusitis
- thrombocytopenia
- urticaria
- vertigo
- weight gain
Monitoring Parameters
- tuberculin skin test
Contraindications
- breast-feeding
- children
- hepatic disease
- hepatitis
- human immunodeficiency virus (HIV) infection
- immunosuppression
- infants
- infection
- neonates
- neoplastic disease
- pregnancy
- renal impairment
- tuberculosis
- vaccination
Interactions
- Alfentanil
- Anakinra
- Bacillus Calmette-Guerin Vaccine, BCG
- Baricitinib
- Basiliximab
- Belladonna Alkaloids; Ergotamine; Phenobarbital
- Brodalumab
- Caffeine; Ergotamine
- Carbamazepine
- Cisapride
- Cyclosporine
- Daclizumab
- Dextromethorphan; Quinidine
- Dihydroergotamine
- Ergotamine
- Ethosuximide
- Everolimus
- Fentanyl
- Fosphenytoin
- Guselkumab
- Influenza Virus Vaccine
- Intranasal Influenza Vaccine
- Ixekizumab
- Live Vaccines
- Measles Virus; Mumps Virus; Rubella Virus; Varicella Virus Vaccine, Live
- Measles/Mumps/Rubella Vaccines, MMR
- Phenytoin
- Pimozide
- Quinidine
- Rilonacept
- Rotavirus Vaccine
- Rubella Virus Vaccine Live
- Sarilumab
- Secukinumab
- Siltuximab
- Sirolimus
- Smallpox and Monkeypox Vaccine, Live, Nonreplicating
- Smallpox Vaccine, Vaccinia Vaccine
- Tacrolimus
- Theophylline, Aminophylline
- Thioridazine
- Tildrakizumab
- Tizanidine
- Tocilizumab
- Tofacitinib
- Tumor Necrosis Factor modifiers
- Typhoid Vaccine
- Upadacitinib
- Ustekinumab
- Varicella-Zoster Virus Vaccine, Live
- Warfarin
- Yellow Fever Vaccine, Live
